2024-513716-95-00CompletedPhase 1
An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in patients with solid tumors
Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 Jul 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- First submitted
- 9 May 2024
- Start date
- 16 May 2022
- Lead sponsor
- Nec Oncoimmunity AS
- EU CT number
- 2024-513716-95-00
- EudraCT number
- 2021-000607-20
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 6
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lietuvos sveikatos mokslu universiteto ligonine Kauno klinikos | Kaunas | Lithuania | Completed |
| Nacionalinis Vezio Institutas | Vilnius | Lithuania | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.